Enable JavaScript to visit this website.

Rheumatology Eligibility Page

This Program is available only to Investigators based in the United States. Both Junior and Senior Investigators are encouraged to apply and consideration will be given to all proposals meeting the selection criteria.

Research Requirements

Hypothesis-testing research is preferred. Uncontrolled pilot and exploratory studies will be considered if reasonably hypothesis-generating. It is expected that the findings will be suitable for presentation at a medical or scientific congress and/or publication in a peer-reviewed journal, and will be submitted to one or both. Proposed studies therefore need to show adequate statistical rigor (for designs with control groups), or be sized for scientific credibility (observational designs).

Criteria for Selection

Awards are determined by the ASPIRE External Review Committees. Each committee is comprised of, of medical and scientific experts in the relevant therapeutic area (rheumatology or gastroenterology).

In their evaluation, the Committee members consider:

  • Scientific merit of the research proposal
  • Qualifications of the Applicant
  • Relevance of proposed research to the program's mission
  • Evidence of the applicant's commitment to an academic research career
  • Evidence of a suitable research environment including, where relevant, adequate access to an appropriate patient population

Other Funding

An ASPIRE Program grant may be complementary to other funding from foundations or government agencies, as long as there is no direct overlap; i.e., the grant application should specify which aspects of the project the ASPIRE award will cover. It is the responsibility of the Applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any other pending funding. ASPIRE Program grants cannot be provided to studies that are already in progress.

Once awarded, an ASPIRE grant cannot be amended upwards with additional funding support from any other competitive grant program from Pfizer, nor can additional drug support above and beyond what is sufficient to complete the original study as reviewed and approved by the Review Committee be provided. If supplemental funding is required, it must be secured from government agencies or foundations outside of Pfizer provided there is no overlap. Similarly, an ongoing Pfizer supported standard IIR cannot apply for supplemental funding via a Pfizer supported competitive grant (ASPIRE) program.

ASPIRE awards cannot be awarded to studies already in progress.


[email protected]